Metabolic profiling in maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Gloyn, Anna L ^a,b   Faber, Johan H ^c   Malmodin, Daniel ^c   Thanabalasingham, Gaya ^a,b   Lam, Francis ^d   Ueland, Per Magne ^e   McCarthy, Mark I ^a,b,f   Owen, Katharine R ^a,b   Baunsgaard, Dorrit ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; BETAINE; BIOLOGICAL MARKER; CHOLINE; GLUCOKINASE; GLUCOSE; GLYCINE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; SARCOSINE; VALINE;

ADULT; AMINO ACID URINE LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETOGENESIS; FEMALE; GENE MUTATION; GENETIC SCREENING; GLUCOSE URINE LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MASS SPECTROMETRY; MATURITY ONSET DIABETES MELLITUS; METABOLIC PROFILING; METABOLISM; METABOLITE; MOLECULAR DIAGNOSIS; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; PARTIAL LEAST SQUARES REGRESSION; PATIENT CODING; PATIENT IDENTIFICATION; PROGNOSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

ADULT; AMINO ACIDS; BETAINE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; FEMALE; GLUCOKINASE; GLYCOSURIA; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED;

EID: 84864487679     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040962     Document Type: Article

References (29)

1. Kropff J, Selwood MP, McCarthy MI, Farmer AJ, Owen KR, ((2011)) Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. Diabetologia 54:: 1261--1263.
2. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, et al. ((2010)) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:: 2504--2508.
3. Murphy R, Ellard S, Hattersley AT, ((2008)) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4:: 200--213.
4. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, et al. ((2003)) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:: 1275--1281.
5. Ellard S, Bellanne-Chantelot C, Hattersley AT, ((2008)) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:: 546--553.
6. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, et al. ((2011)) A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54:: 2801--2810.
7. Servitja JM, Pignatelli M, Maestro MA, Cardalda C, Boj SF, et al. ((2009)) Hnf1alpha (MODY3) controls tissue-specific transcriptional programs and exerts opposed effects on cell growth in pancreatic islets and liver. Mol Cell Biol 29:: 2945--2959.
8. Bingham C, Ellard S, Nicholls AJ, Pennock CA, Allen J, et al. ((2001)) The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria. Diabetes 50:: 2047--2052.
9. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, et al. ((2010)) An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 267:: 316--321.
10. Karlsson E, Shaat N, Groop L, ((2008)) Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)? Diabet Med 25:: 788--791.
11. Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, et al. ((2010)) Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 33:: 1919--1924.
12. Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, et al. ((2010)) Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 33:: 252--257.
13. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, et al. ((2003)) Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 52:: 2989--2995.
14. Skupien J, Gorczynska-Kosiorz S, Klupa T, Wanic K, Button EA, et al. ((2008)) Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. Diabetes Care 31:: 1496--1501.
15. Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebska A, Klupa T, et al. ((2007)) Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY. Rev Diabet Stud 4:: 231--235.
16. Stride A, Pearson ER, Brown A, Gooding K, Castleden HA, et al. ((2004)) Serum amino acids in patients with mutations in the hepatocyte nuclear factor-1 alpha gene. Diabet Med 21:: 928--930.
17. McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, et al. ((2011)) High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care. 34:: 1860--1862.
18. Bonzo JA, Patterson AD, Krausz KW, Gonzalez FJ, ((2010)) Metabolomics identifies novel Hnf1alpha-dependent physiological pathways in vivo. Mol Endocrinol 24:: 2343--2355.
19. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. ((2011)) Metabolite profiles and the risk of developing diabetes. Nat Med 17:: 448--453.
20. Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, et al. ((2011)) Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 286:: 19511--19522.
21. Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, et al. ((2005)) Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care 28:: 1751--1756.
22. Pontoglio M, Prie D, Cheret C, Doyen A, Leroy C, et al. ((2000)) HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep 1:: 359--365.
23. Ueland PM, ((2011)) Choline and betaine in health and disease. J Inherit Metab Dis 34:: 3--15.
24. Dellow WJ, Chambers ST, Lever M, Lunt H, Robson RA, ((1999)) Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. Diabetes Res Clin Pract 43:: 91--99.
25. Lever M, George PM, Dellow WJ, Scott RS, Chambers ST, ((2005)) Homocysteine, glycine betaine, and N, N-dimethylglycine in patients attending a lipid clinic. Metabolism 54:: 1--14.
26. Lever M, Slow S, McGregor DO, Dellow WJ, George PM, et al. ((2012)) Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study. Cardiovasc Diabetol 11:: 34.
27. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G, ((2006)) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78:: 779--787.
28. Dieterle F, Ross A, Schlotterbeck G, Senn H, ((2006)) Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem 78:: 4281--4290.
29. Wiklund S, Johansson E, Sjostrom L, Mellerowicz EJ, Edlund U, et al. ((2008)) Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 80:: 115--122.